Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11749979 | 0.89 | CHRM2 (0.51) | CHRM2ADORA3KCNH2CNR1GPR55 | |
| SCHEMBL5483580 | 0.88 | CHRM2 (0.62) | CHRM2ADORA3KCNH2CNR1GPR55 | |
| SCHEMBL11749977 | 0.86 | CHRM2 (0.48) | CHRM2ADORA3KCNH2CNR1GPR55 | |
| SCHEMBL7031893 | 0.83 | CHRM2 (0.85) | CHRM2ADORA3KCNH2CNR1GPR55 | |
| SCHEMBL5483163 | 0.81 | CHRM2 (0.62) | CHRM2ADORA3KCNH2CNR1GPR55 | |
| SCHEMBL5478164 | 0.81 | CHRM2 (0.62) | CHRM2ADORA3KCNH2CNR1GPR55 | |
| SCHEMBL5486582 | 0.81 | CHRM2 (0.62) | CHRM2ADORA3KCNH2CNR1GPR55 | |
| SCHEMBL5479245 | 0.81 | CHRM2 (0.62) | CHRM2ADORA3KCNH2CNR1GPR55 | |
| SCHEMBL5483481 | 0.81 | CHRM2 (0.62) | CHRM2ADORA3KCNH2CNR1GPR55 | |
| SCHEMBL5478595 | 0.81 | CHRM2 (0.57) | CHRM2ADORA3KCNH2CNR1GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | claimed |
| EP-1734951-A2 | DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TopoTarget A/S (DK) | 2006-12-27 | — | — | EP | claimed |
| WO-2005097107-A2 | DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TOPOTARGET A/S (DK) | 2005-10-20 | — | — | WO | claimed |
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | disclosed |
| EP-1734951-A2 | DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TopoTarget A/S (DK) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097107-A2 | DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TOPOTARGET A/S (DK) | 2005-10-20 | — | — | WO | disclosed |
| US-4053483-A | DERIVATIVES OF 3,3-BIS-(4-HYDROXYPHENYL)-2-INDOLINONE AND PROCESS FOR THE PREPARATION THEREOF | DOCTOR ANDREU S.A. (ES) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | MTOR, RICTOR, CDK4 | CHRM2 2994/4885ADORA3 3566/4885KCNH2 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.